SriniVas Sadda, MD; Anthony DeFino , 2025-06-24 18:28:00
June 24, 2025
3 min watch
LAS VEGAS — In this Healio Video Perspective from Clinical Trials at the Summit, SriniVas R. Sadda, MD, FARVO, discusses the challenges of using the ellipsoid zone as a trial endpoint.
“It is exciting that the FDA at least has indicated that the status of the photoreceptors, their preservation over time, is an important endpoint for trials, but they didn’t really get into the weeds about how do we actually measure it,” he said.
According to Sadda, challenges with using the ellipsoid zone (EZ) include inconsistent terminology for EZ integrity and issues with visualization of the EZ band. In age-related macular degeneration, disease features such as drusen may affect EZ assessment.
Sadda suggested that the EZ may not be a sensitive marker for photoreceptor loss compared with other markers such as the outer nuclear layer.
“Even if you are able to show with a therapy that the EZ is preserved, we don’t know whether that preserved EZ is functional,” Sadda said.
Sources/Disclosures
Collapse
Sadda S. Opportunities and challenges for the EZ as a trial endpoint. Presented at: Clinical Trials at the Summit; June 21, 2025; Las Vegas.
Disclosures:
Sadda reports no relevant financial disclosures.
